Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Kidney Transplantation
Both
Kidney Transplantation
Trial Information
Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)
Time Perspective: Prospective design, Retrospective data collection and analysis
Inclusion Criteria:
- 1st kidney only transplant during study, at one of the transplant centers
participating in CTS, received Belatacept or a CNI at the time of transplantation
Exclusion Criteria:
- Patients with a history of malignancy
Type of Study:
Observational
Study Design:
Observational Model: Cohort
Outcome Measure:
Incidences of Post-transplant Lymphoproliferative Disorder (PTLD)
Outcome Time Frame:
5 years post transplantation
Safety Issue:
Yes
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
European Union: European Medicines Agency
Study ID:
IM103-089
NCT ID:
NCT01471223
Start Date:
April 2012
Completion Date:
February 2021
Related Keywords:
- Kidney Transplantation
Name | Location |
|---|
